WooGene B&G Co., Ltd

A018620

KR7018620005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
1,127 ^KRW	-2.25%		-5.05%	-8.00%

03-20	WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

WooGene B&G Co., Ltd. announced that it has received KRW 3 billion in funding

January 14, 2020

On January 15, 2020, WooGene B&G Co., Ltd. (KOSDAQ:A018620) closed the transaction.

Latest news about WooGene B&G Co., Ltd

WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
WooGene B&G Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
WooGene B&G Co., Ltd announced that it has received KRW 8 billion in funding	23-03-22	CI
WooGene B&G Co., Ltd announced that it expects to receive KRW 8 billion in funding	23-03-20	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
WooGene B&G Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-22	CI
WooGene B&G Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
An unknown buyer cancelled the acquisition of 23.2% stake in WooGene Bio Co., Ltd. from WooGene B&G Co., Ltd..	20-12-15	CI
WooGene B&G Co., Ltd. announced that it has received KRW 3 billion in funding	20-01-14	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 3 billion in funding	20-01-09	CI
An unknown buyer agreed to acquire 23.2% stake in WooGene Bio Co., Ltd. from WooGene B&G Co., Ltd. for KRW 2.9 billion.	19-12-15	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 7.526523 billion in funding from Green Cross Veterinary Products Co., Ltd.	19-12-15	CI
WooGene B&G Co., Ltd. announced that it has received KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd. and other investor	19-10-13	CI
WooGene B&G Co., Ltd. agreed to acquire OSP Co., Ltd. from Taejun Kim, Hyewon Kim and Jiwon Kim for KRW 22.5 billion.	19-10-13	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd.and another investor	19-09-30	CI
WooGene B&G Co., Ltd. announced that it has received KRW 5 billion in funding	19-06-02	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 5 billion in funding	19-05-29	CI
WooGene B&G Co., Ltd. announced that it has received KRW 13 billion in funding from Hyundai Asset Management Co., Ltd.	16-05-19	CI
WooGene B&G Co., Ltd. announced that it expects to receive KRW 11 billion in funding from Hyundai Asset Management Co., Ltd. and other investors.	16-05-15	CI
WooGene B&G Co., Ltd.’s Equity Buyback announced on October 10, 2008 has expired.	14-05-02	CI
WooGene B&G Co., Ltd. Extends Equity Buyback till May 2, 2014	13-04-30	CI

WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
WOOGENE B&G CO., LTD	-8.00%	22.99M
ELANCO ANIMAL HEALTH INCORPORATED	+19.80%	8.82B
BLUESTAR ADISSEO COMPANY	+21.88%	3.6B
VIRBAC	-7.37%	3B
VIMIAN GROUP AB	+12.84%	1.65B
VETOQUINOL SA	-6.54%	1.22B
JINYU BIO-TECHNOLOGY CO., LTD.	-33.05%	1.11B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-35.50%	1.08B
WUHAN KEQIAN BIOLOGY CO.,LTD	-27.33%	948M
SWEDENCARE AB	-1.57%	936M